This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Patiromer calcium oral powder


Powder for oral suspension containing patiromer calcium.

Drugs List

  • patiromer calcium 16.8g oral powder
  • patiromer calcium 8.4g oral powder
  • VELTASSA 16.8g oral powder
  • VELTASSA 8.4g oral powder
  • Therapeutic Indications





    Initial dose: 8.4g once daily.

    The daily dose may be increased or decreased by 8.4g up to a maximum dose of 25.2g daily. The daily dose may be adjusted in intervals of one week or longer, based on the serum potassium level and the desired target range. Reduce or discontinue patiromer calcium if the serum potassium level falls below the desired range.


    Children under 18 years
    Hereditary fructose intolerance

    Precautions and Warnings

    Gastrointestinal disorder
    History of gastrointestinal obstruction
    History of major gastrointestinal surgery
    Renal dialysis
    Renal impairment - eGFR below 15ml/minute/1.73m sq

    Presentations with sorbitol unsuitable in hereditary fructose intolerance
    Advise patient to avoid other oral medicines 3 hours before or after dose
    Monitor serum magnesium for at least 1 month after initiating treatment
    Monitor serum potassium regularly
    Magnesium supplements may be required
    Advise patient to consult doctor before discontinuing therapy

    The onset of action can be expected 4 to 7 hours after administration of patiromer calcium.

    Patiromer calcium does not replace emergency treatment for life threatening hyperkalaemia.

    Limited experience exists in patients with a serum potassium concentration greater than 6.5mmol/L.

    Serum potassium levels may increase as soon as 2 days after the last dose of patiromer calcium.

    Pregnancy and Lactation


    Use patiromer calcium with caution during pregnancy.

    At the time of writing, there are no data from the use of patiromer in pregnant women.

    The manufacturer advises that it is preferable to avoid its use as a precautionary measure although animal studies have not indicated any harmful effects either directly or indirectly.


    Use patiromer calcium with caution during breastfeeding.

    The manufacturer recommends that a decision must be made whether to discontinue breastfeeding or to discontinue patiromer taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.

    No effects on the breastfed infant are anticipated as the systemic exposure to patiromer of the breastfeeding woman is negligible.

    Side Effects

    Abdominal pain


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: August 2019

    Reference Sources

    Summary of Product Characteristics: Veltassa (Patiromer). Vifor Fresenius Medical Care Renal Pharma UK Ltd. Revised June 2019.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.